ABSTRACT
The murine model was developed to assess the effects of maternally transferred HIV hyperimmune globulin or human intravenous immune globulin on the immunization of the offspring at 18-21 days of age with rgp 120SF2-complete Freund's adjuvant. Either HIV hyperimmune globulin or intravenous immune globulin was administered intraperitoneally to post-partum BALB/c mice and was transferred via milk to the offspring. Both HIV hyperimmune globulin and intravenous immune globulin inhibited the offspring anti-rgp 120SF2 IgG response to the vaccine. The HIV hyperimmune globulin inhibition persisted for 28 days after immunization while the intravenous immune globulin inhibition was still present at 63 days after immunization. In addition, the intravenous immune globulin had a more generalized immunosuppressive effect, inhibiting the IgG response to both rpg 120SF2 and an additional protein antigen, hen egg-white lysozyme. Effects of maternal or exogenously administered pre-existing antibody, including control antibodies (intravenous immune globulin), on the newborn response to HIV and other vaccines must be carefully evaluated when vaccine studies proceed in newborns.
Subject(s)
AIDS Vaccines/pharmacology , HIV Antibodies/pharmacology , Immunity, Maternally-Acquired/drug effects , Immunoglobulins, Intravenous/pharmacology , AIDS Vaccines/immunology , Amino Acid Sequence , Animals , Disease Models, Animal , Female , HIV Envelope Protein gp120/immunology , Humans , Immunoglobulin G/analysis , Immunoglobulin G/drug effects , Mice , Mice, Inbred BALB C , Molecular Sequence DataABSTRACT
Five chimpanzees were immunized by administration of one or more intranasal priming doses of one to three recombinant adenoviruses containing a gp160 insert from human immunodeficiency virus type 1 (HIV-1) MN (HIV-1MN) followed by one or more boosts of recombinant HIV-1SF2 gp120 delivered intramuscularly with MF59 adjuvant. This regimen resulted in humoral immune responses in three of five animals. Humoral responses included immunochemically active anti-H1V-1 antibodies (Abs) directed to recombinant gp120 and neutralizing Abs reactive with T-cell-line-adapted HIV-1MN and HIV-1SF2. In addition, neutralizing activity was detected to the two homologous primary isolates and to two of three heterologous primary isolates which, like the immunizing strains, can use CXCR4 as a coreceptor for infection. The three animals with detectable neutralizing Abs and a fourth exhibiting the best cytotoxic T-lymphocyte response were protected from a low-dose intravenous challenge with a cell-free HIV-1SF2 primary isolate administered 4 weeks after the last boost. Animals were rested for 46 weeks and then rechallenged, without a boost, with an eightfold-higher challenge dose of HIV-1SF2. The three animals with persistent neutralizing Abs were again protected. These data show that a strong, long-lived protective Ab response can be induced with a prime-boost regimen in chimpanzees. The data suggest that in chimpanzees, the presence of neutralizing Abs correlates with protection for animals challenged intravenously with a high dose of a homologous strain of HIV-1, and they demonstrate for the first time the induction of neutralizing Abs to homologous and heterologous primary isolates.
Subject(s)
Antibodies, Viral/immunology , HIV Envelope Protein gp160/immunology , HIV-1/immunology , T-Lymphocytes/immunology , Viral Vaccines , Animals , Antigens, Viral/immunology , Humans , Immunization , Pan troglodytesABSTRACT
Small animals were immunized with plasmid DNA encoding HIV-1 envelope gp120 either intramuscularly by needle injection (mice and guinea pigs) or epidermally with the Accell gene gun (guinea pits). Subsequently, the animals were boosted with a recombinant gp120 protein subunit vaccine in an oil-in-water based adjuvant, MF59. Antibodies and cytotoxic T-lymphocyte (CTL) immune responses to the HIV envelope glycoprotein were observed in animals immunized with gp120 DNA derived from the HIV-1SF2 laboratory strain or from HIV-1 field isolates. Titers of ELISA antibodies and serum neutralizing antibodies against the HIV-1SF2 laboratory isolate were substantially increased in DNA-immunized animals following a single boost with recombinant gp120 protein subunit. This DNA prime/protein subunit boost immunization approach may be important for vaccination against infectious agents such as HIV for which it is difficult to raise strong antiviral humoral responses with DNA vaccination alone.
Subject(s)
AIDS Vaccines/immunology , HIV Antibodies/biosynthesis , HIV Envelope Protein gp120/immunology , Vaccines, DNA/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/genetics , Acquired Immunodeficiency Syndrome/prevention & control , Adjuvants, Immunologic , Animals , Biolistics , DNA, Viral/immunology , Enzyme-Linked Immunosorbent Assay , Guinea Pigs , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp120/genetics , Injections, Intramuscular , Mice , Mice, Inbred BALB C , Plasmids/genetics , Polysorbates/analysis , Squalene/analysis , Squalene/immunology , Surface-Active Agents , T-Lymphocytes, Cytotoxic/immunology , Vaccination , Vaccines, DNA/administration & dosage , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunologyABSTRACT
In contrast to results obtained with plasmid DNA vectors encoding antigens from viruses such as influenza and hepatitis B, plasmids coding for antigens from primate immunodeficiency viruses have elicited relatively weak antibody responses following gene gun-mediated DNA immunization of rhesus monkeys. In an effort to augment these responses, the importance of the immunization schedule was investigated, as well as the possible synergy that might result from boosting gene gun-primed animals with other routes of immunization. Here we demonstrate that endpoint gp120-specific antibody titers can be enhanced as much as tenfold by reducing the number of immunizations and lengthening the resting period between immunizations. In addition, boosting gene gun-primed animals with either recombinant subunits or gp120-expressing vaccinia recombinants resulted in synergistic responses.
Subject(s)
AIDS Vaccines/immunology , HIV Antibodies/biosynthesis , HIV-1/immunology , Membrane Glycoproteins , Simian Immunodeficiency Virus/immunology , Vaccines, DNA/immunology , Viral Envelope Proteins , AIDS Vaccines/administration & dosage , AIDS Vaccines/genetics , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/prevention & control , Animals , Antibodies, Viral/biosynthesis , Biolistics , DNA, Viral/immunology , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/immunology , HIV-1/genetics , Immunization Schedule , Immunoglobulin G/analysis , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/genetics , Vaccines, DNA/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccinia virus/immunologyABSTRACT
A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to low-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.
Subject(s)
Adenoviridae/immunology , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp160/immunology , HIV-1/pathogenicity , Recombinant Fusion Proteins/immunology , Vaccination/methods , Animals , Female , HIV Infections/immunology , HIV Infections/prevention & control , Pan troglodytes , Recombinant Fusion Proteins/administration & dosage , T-Lymphocytes, Cytotoxic/physiology , Vaccines/administration & dosageABSTRACT
The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic differences between the vaccine and the strains tested, insensitivity of the assays used, or to a combination of factors. New neutralization assays were used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for clade B primary isolate BZ167, which is closely related in portions of its envelope to the immunizing strains. Sera from HIV-uninfected volunteers in vaccine trials were tested, and neutralizing activity was found in recipients of recombinant (r) gp120MN or of rgp160MN-containing canarypox boosted with rgp120SF-2. Detection of antibodies that neutralize primary isolate BZ167 correlated with neutralizing activity for homologous vaccine strains. These data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1.
Subject(s)
AIDS Vaccines/immunology , HIV Antibodies/blood , HIV-1/immunology , Adolescent , Adult , Female , HIV Envelope Protein gp120/immunology , Humans , Male , Middle AgedABSTRACT
Haematologic abnormalities accompany the majority of HIV-1 infections. At present it is unclear whether this is due directly to HIV infection of hematopoietic progenitor cells, or whether this results from an indirect mechanism secondary to HIV infection. Here we provide evidence for an indirect mechanism, whereby hematopoietic progenitor cells undergo HIV gp120-induced apoptosis (programmed cell death) even in the absence of HIV infection. Freshly isolated, purified human hematopoietic progenitor CD34+ cells, derived from both umbilical cord blood and bone marrow, co-expressed the CD4 marker at low density on their surface. Although these CD34+CD4+ cells theoretically should be capable of productive infection by HIV, we found that HIV-IIIB could not establish productive infection in these cells. Nonetheless, gp120 from IIIB could bind the cells. Thus, binding of gp120 did not correlate with infectivity. Furthermore, binding of gp120 was a specific event, leading to apoptosis upon crosslinking with anti-gp120 through a fas-dependent mechanism. If apoptosis is also observed in vivo even in uninfected hematopoietic cells, this could contribute significantly to the impairment in hematopoietic cell number and function. Our data suggest a novel indirect mechanism for depletion of CD34+ and CD34+-derived cells even in the absence of productive viral infection of these cells.
ABSTRACT
The effect of maternally transferred monoclonal antibody (MAb) on the offspring antibody response to rgp120SF2 was examined in a murine model. Two MAbs were studied: MAb 83.1, which recognizes a determinant in the V3 loop of gp120 from human immunodeficiency virus-1 (HIV-1) SF2, and MAb 26.2D3, which recognizes a conserved N-terminal region of gp120 from HIV-1SF2. Offspring were immunized at 18-21 days of age with 100 micrograms of rgp120SF2 in complete Freund's adjuvant. Offspring immunized in the presence of preexisting MAb 83.1 but not MAb 26.2D3 demonstrated inhibition of the IgG anti-V3 response. The total IgG anti-rgp120SF2 response was not affected by preexisting MAb. Since newborns at risk for HIV may be immunized in the presence of maternal or administered anti-HIV antibody, alternative strategies may be required to circumvent inhibition of the infant's epitope-specific response to HIV immunization by preexisting antibody.
Subject(s)
AIDS Vaccines/immunology , Antibodies, Monoclonal/immunology , HIV Antibodies/blood , HIV Envelope Protein gp120/immunology , Immunity, Maternally-Acquired , Vaccines, Synthetic/immunology , Amino Acid Sequence , Animals , Antibody Specificity , Female , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Molecular Sequence Data , PregnancyABSTRACT
A large stock preparation of the HIV-1SF2 isolate has been derived after serial passage in human peripheral blood mononuclear cells (PBMCs). This viral stock has a titer of 10(4.9) TCID50 in human PBMCs and 10(4.2) TCID50 in chimpanzee PBMCs. By inoculation into animals the 50% chimpanzee infectious dose titer was found to be about 10(2.3). Virus isolation from animals was achieved on most occasions within 1-4 weeks after inoculation and then became transient. Viral RNA and DNA PCR analyses confirmed the virus infection of the chimpanzees. Anti-HIV antibody levels in the inoculated animals ranged from 1:400 to 1:6400 as measured by ELISA. About 680 vials of this stock preparation, frozen at -190 degrees C, are available for future studies of vaccines and antiviral therapies.
Subject(s)
AIDS Vaccines , HIV-1 , Animals , DNA, Viral/chemistry , Enzyme-Linked Immunosorbent Assay , HIV-1/pathogenicity , Humans , Pan troglodytes , Polymerase Chain Reaction , RNA, Viral/chemistryABSTRACT
A flow cytometric assay based on expression of the activation antigen CD69 was developed to analyze immunological responses of T cells from human immunodeficiency virus (HIV)-infected (HIV+) or HIV-seronegative (HIV-) donors after in vitro simulation by antigens and polyclonal activators. The levels of CD69 on freshly-isolated or unstimulated, cultured CD3+, CD4+, or CD8+ peripheral blood lymphocyte (PBL) subsets were low and did not differ greatly between HIV+ and HIV- donors. The frequencies of CD3+, CD4+, and CD8+ lymphocytes from HIV+ donors that expressed CD69 after culture with antigenic or mitogenic stimuli were significantly lower than in HIV- donors. Comparison of CD69 expression with [3H]thymidine incorporation revealed that both assays could detect lymphocyte responses to antigenic or mitogenic stimuli. The CD3+ PBL from HIV+ or HIV- donors did not show increased CD69 expression after culture with soluble or cross-linked recombinant envelope glycoprotein, gp120. The gp120, however, significantly inhibited CD69 expression in phytohemagglutinin-stimulated T cells in vitro and may also affect T-cell activation in vivo. These studies demonstrate the usefulness of this CD69 expression assay for the rapid assessment of defects in immune responses of phenotypically defined lymphocyte subsets in HIV+ patients and for testing the effects of agents that modulate immune activation.
Subject(s)
Antigens, CD/biosynthesis , Antigens, Differentiation, T-Lymphocyte/biosynthesis , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , HIV Infections/immunology , Lymphocyte Activation , CD3 Complex/immunology , Cells, Cultured , DNA Replication , Flow Cytometry , HIV Envelope Protein gp120/pharmacology , HIV Seropositivity/immunology , Humans , Immunophenotyping , Lectins, C-Type , Lymphocyte Activation/drug effects , Male , Mitogens/pharmacology , Prospective Studies , Recombinant Proteins , Thymidine/metabolismABSTRACT
OBJECTIVE: To determine whether vaccination with recombinant HIV-1SF2 gp120 in a novel oil-in-water adjuvant emulsion, MF59, protects chimpanzees against challenge with HIV-1SF2, the homologous virus isolate. METHODS: Two vaccinated chimpanzees and two control animals were challenged with 25-50 animal infectious doses of a stock of HIV-1SF2 that had been grown in mitogen-activated human peripheral blood mononuclear cells (PBMC). The animals were monitored by a series of serologic [enzyme-linked immunosorbent assay (ELISA), Western blot, and neutralization assays] and virologic [virus culture, RNA and DNA polymerase chain reaction (PCR)] assays for infection. RESULTS: Both control animals showed evidence of seroconversion in ELISA and Western blot assays. In addition, virus was detected in the early, acute phase of infection of both control animals by (1) plasma RNA PCR, (2) virus culture, and (3) PBMC DNA PCR assays. One vaccinated animal showed no serologic or virologic evidence of infection. The other vaccinated animal has not seroconverted, and there was no evidence of plasma viremia. However, virus was detected at early timepoints in this animal's PBMC, and transient lymphoproliferation to HIV-1 proteins not in the vaccine was observed. These observations suggest that the former animal was protected from challenge while the latter may have experienced a transient or curtailed infection. CONCLUSION: Two types of vaccine-induced protective immune responses were observed when chimpanzees immunized with rgp120SF2 were challenged with the homologous virus isolate: a response consistent with the 'sterilizing immune response' documented in the chimpanzee model in previous studies, as well as one that did not completely protect from infection, showing curtailment of the acute phase and a failure of the animal to seroconvert.
Subject(s)
AIDS Vaccines/therapeutic use , HIV Envelope Protein gp120/immunology , HIV Infections/prevention & control , HIV-1/immunology , Vaccination , Vaccines, Synthetic/therapeutic use , Amino Acid Sequence , Animals , Blotting, Western , Enzyme-Linked Immunosorbent Assay , HIV Antibodies/blood , HIV Infections/blood , Lymphocyte Activation , Molecular Sequence Data , Neutralization Tests , Pan troglodytes , Polymerase Chain Reaction , Virus CultivationABSTRACT
A murine model was developed for assessing the effects of passively transferred polyclonal maternal anti-gp120 antibodies on the subsequent immunization of the offspring with recombinant gp120SF2 in complete Freund's adjuvant (rgp120SF2-CFA). Adult female BALB/c mice were immunized with rgp120SF2-CFA 6 weeks before mating. The 3-week-old offspring were subsequently immunized with the same vaccine and followed for 9 weeks. Both the total IgG anti-rgp120SF2 and the anti-V3 IgG antibody response to vaccine were inhibited in the experimental animals. The total IgG anti-rgp120SF2 response was < 20% of the control response (P < .001) 9 weeks after immunization. Anti-V3 antibody was also decreased. As vaccine studies begin in infants, the effects of preexisting antibody on the infant response to human immunodeficiency virus vaccines must be considered.
Subject(s)
AIDS Vaccines/immunology , Antibodies, Viral/biosynthesis , HIV Envelope Protein gp120/immunology , Immunity, Maternally-Acquired/immunology , Peptide Fragments/immunology , Amino Acid Sequence , Animals , Female , HIV-1/immunology , Immunization, Passive , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Recombinant Proteins/immunologyABSTRACT
A vaccine breakthrough occurred in a phase 1 clinical trial of a human immunodeficiency virus (HIV) type 1 candidate subunit vaccine. The vaccine antigen, gp120SF2, is a fully glycosylated protein produced in mammalian cells from the HIVSF2 isolate. After 4 immunizations, the subject developed neutralizing antibodies and lymphoproliferative responses to the gp120 protein. About 18 weeks after the last immunization, the subject became HIV infected. During the acute phase of infection, there was high virus burden, a decline in CD4+ T lymphocytes, increases in rgp120SF2-binding antibodies and HIVSF2- and HIVMN-neutralizing antibodies, and transient lymphoproliferative responses to HIV-1 envelope and core proteins. The nucleotide sequence of the V3 loop from 2 virus isolations displayed close similarity to the V3 sequence of the vaccine antigen. Thus, the immunologic responses induced by the vaccine in this subject did not protect him from HIV-1 infection.
Subject(s)
AIDS Vaccines/immunology , HIV Envelope Protein gp120/immunology , HIV Infections/immunology , HIV-1/immunology , Adult , Amino Acid Sequence , CD4 Lymphocyte Count , HIV Antibodies/blood , HIV Envelope Protein gp120/genetics , HIV Infections/prevention & control , HIV Infections/virology , HIV-1/genetics , Homosexuality, Male , Humans , Immunity, Active , Male , Molecular Sequence Data , Neutralization Tests , Peptide Fragments/genetics , RNA, Viral/blood , RNA, Viral/genetics , Sequence Analysis, DNA , VaccinationABSTRACT
A phase 1 study of 42 non-human immunodeficiency virus type 1 (HIV)-infected volunteers was initiated to determine the safety and immunogenicity of an HIV subunit vaccine consisting of recombinant envelope gp120 derived from HIVSF2 (rgp120SF2) combined with a novel adjuvant, MF59, with or without the immunomodulator muramyl tripeptide dipalmitoyl phosphatidylethanolamine (MTP-PE). All injections contained adjuvant MF59, and subjects were grouped according to MTP-PE dose. Injections were given on days 0, 30, 180, and 365. The vaccine was well tolerated with limited local and systemic reactions. These immunizations induced rgp120SF2-specific binding antibodies that persisted > or = 24 weeks. After three immunizations, all subjects receiving the antigen developed neutralizing antibodies to HIVSF2, and serum from 67% of these subjects also cross-neutralized HIVMN. ELISA-reactive antibodies to the HIVSF2 V3 region and strong lymphoproliferative responses to HIVSF2 envelope proteins were detected in all rgp120SF2-immunized subjects.
Subject(s)
AIDS Vaccines/immunology , Acetylmuramyl-Alanyl-Isoglutamine/analogs & derivatives , Adjuvants, Immunologic/administration & dosage , HIV Envelope Protein gp120/immunology , Phosphatidylethanolamines/administration & dosage , Polysorbates/administration & dosage , Squalene/administration & dosage , Vaccines, Synthetic/immunology , AIDS Vaccines/administration & dosage , Acetylmuramyl-Alanyl-Isoglutamine/administration & dosage , Adolescent , Adult , Double-Blind Method , Female , HIV Antibodies/blood , Humans , Immunization , Male , Middle Aged , Vaccines, Synthetic/administration & dosageABSTRACT
Priming of CD8+ cytotoxic T lymphocyte (CTL) responses with recombinant proteins has been facilitated by the development of novel adjuvants that deliver antigens into the class I major histocompatibility complex (MHC) pathway. However, the extent to which secondary structure or glycosylation of these proteins prevents priming of class I MHC-restricted CTL responses is not clear. To address this issue, recombinant HIV-1 gp120 envelope proteins produced in yeast insect, or mammalian cells were compared for the ability to elicit CD8+ CTL activity in mice. Envelope-specific CD8+ T lymphocytes were detected in BALB/c mice immunized with env 2-3, a 55-kDa yeast-derived envelope protein that is not glycosylated and lacks a native conformation. This response was directed against a previously described epitope in the V3 region of gp120, as well as a newly identified epitope located near the carboxy-terminus of the molecule. Similar levels of V3-directed CTL activity were observed in mice immunized with recombinant gp120 produced in insect (Spodoptera fugiperda) cells using a baculovirus expression system (gp120BAC). In contrast, induction of CTL responses was considerably less efficient when mice were immunized with gp120CHO, a native, fully glycosylated envelope protein produced in mammalian CHO cells. Denaturation of gp120CHO prior to immunization was not sufficient to prime CTL responses. However, envelope-specific CD8+ CTL activity was elicited when N-linked glycans were removed by treatment with an endoglycosidase. Possible mechanisms by which N-linked glycans influence delivery or processing of recombinant proteins for class I MHC presentation, and the implications of these findings for the design of subunit vaccines, are discussed.
Subject(s)
Glycoproteins/immunology , HIV Envelope Protein gp120/chemistry , HIV-1/immunology , Recombinant Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Cytotoxicity, Immunologic , Epitopes , Female , HIV Envelope Protein gp120/immunology , Immunity, Cellular , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Peptides/chemistry , Recombinant Proteins/chemistry , Structure-Activity RelationshipABSTRACT
We have described previously the generation of seven HIV-SF2 Nef-specific, CD4+ T-cell clones, identification of epitopes within which are recognized by these clones, and the MHC alleles that restrict their responses. In this study, we have extended this characterization to include evaluation of antigen-processing and presentation requirements and cytotoxic activity. Clones were generated from five HIV-1 uninfected donors by in vitro stimulation of peripheral blood mononuclear cells with purified recombinant Nef1. In experiments with fixed cells, with the exception of two clones, recognition of Nef, but not Nef peptides, required processing. Also, at higher concentrations of antigen, the clones themselves were capable of presenting Nef peptides, but not soluble Nef. All clones had the ability to specifically lyse autologous, Epstein-Barr virus-transformed lines sensitized with Nef synthetic peptides, or, in some cases, soluble Nef. The cytotoxic activity mapped to the same epitopes identified for the proliferative response (a.a. 14-22, 47-53, 68-77, 70-77, 195-203 and 185-192) and was restricted by the same HLA class II molecules (DRw6, DQw7, DRw15(2), DR1 and DP5). Sensitization of the cytolytic clones with specific Nef peptides, but not soluble Nef, resulted in autolysis.
Subject(s)
Antigen Presentation , CD4-Positive T-Lymphocytes/immunology , Cytotoxicity, Immunologic , Gene Products, nef/immunology , HIV-1/immunology , Alleles , Amino Acid Sequence , Cells, Cultured , Clone Cells , Genes, MHC Class II , Humans , Lymphocyte Activation , Molecular Sequence Data , Recombinant Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , nef Gene Products, Human Immunodeficiency VirusABSTRACT
Human T-cell clones with specificity to the HIV-1 nef protein were generated by the in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from HIV-1-seronegative donors with purified nef from the HIV-SF2 isolate produced in genetically engineered yeast. Here the characterization is described of a total of seven discrete clones derived from five different donors. Each clone was CD3+ CD4+ CD8- as determined by FACS analysis. The epitopes recognized by these clones were identified using synthetic overlapping peptides spanning the entire length of nef. Six discrete helper T-cell epitopes located in five distinct regions of nef were identified by this approach. Three of these epitopes are more than 80% conserved among all HIV-1 nef proteins for which sequence data are available. The remaining epitopes are in regions of nef that vary among isolates. Many of the epitopes recognized by our clones overlap T-cell epitopes identified by others examining T-cell responses to nef in HIV-1-infected patients and immunized animals. Using partially class II-matched EBV-transformed B-cell lines, we were able to identify five different HLA class II alleles which encode restricting elements for the in vitro nef-specific proliferative response of these clones (DR1, DRw15(2), DRw6, DQw7, DP5).
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Gene Products, nef/immunology , HIV-1/immunology , Adult , Amino Acid Sequence , Clone Cells/immunology , Cross Reactions , Epitopes/genetics , Gene Products, nef/genetics , HIV Seronegativity/immunology , HIV-1/genetics , Histocompatibility Antigens Class II , Humans , In Vitro Techniques , Lymphocyte Activation , Molecular Sequence Data , Peptide Fragments/genetics , Peptide Fragments/immunology , nef Gene Products, Human Immunodeficiency VirusABSTRACT
This report compares the immunogenicity of three different preparations of gp120 [the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) virus]: (a) native, fully glycosylated gp120; (b) a nonglycosylated, denatured form of gp120; and (c) a nonglycosylated peptide representing the "immunodominant" third hypervariable region of the gp120 molecule. Results indicate that the native glycosylated form of gp120 induces a maximal anti-HIV response in which a majority of B cells bind to conformation-dependent epitopes but less than one-fifth recognize the V3 loop region.
Subject(s)
Antibody Formation , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Animals , B-Lymphocytes/immunology , CHO Cells , Cricetinae , Cross Reactions , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Female , Genetic Variation , Glycosylation , HIV Antibodies/analysis , HIV Antibodies/isolation & purification , Mice , Mice, Inbred BALB C/immunology , Protein Conformation , Protein DenaturationSubject(s)
HIV Antibodies/immunology , HIV Envelope Protein gp120/immunology , HIV/immunology , Immunization , Primates/immunology , Recombinant Proteins/immunology , Amino Acid Sequence , Animals , Epitopes/immunology , HIV Antibodies/biosynthesis , Molecular Sequence Data , Neutralization Tests , Papio/immunology , Protein ConformationABSTRACT
Chimpanzees infected with human immunodeficiency virus type 1 produce antibodies against the variable regions of the external envelope glycoprotein gp120. All five variable regions contain an epitope which is recognized by at least one of five chimpanzee sera. Each of the sera recognized a different pattern of epitopes. It is suggested that this varying response contributes to the emergence of variant viruses in the host. In contrast with the variability of the chimpanzees' response to replicating virus, that of baboons to a candidate recombinant vaccine is more uniform. Baboons injected with recombinant gp120 produced high levels of antibodies to epitopes within both the variable and conserved regions which coincided with epitopes previously shown to induce neutralizing antibodies.